| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14712598.5.2.207 |
| P698 | PubMed publication ID | 15757382 |
| P2093 | author name string | Hagen Cramer | |
| P2860 | cites work | Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription | Q24535577 |
| RNA virus error catastrophe: direct molecular test by using ribavirin | Q24599371 | ||
| Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses | Q24797827 | ||
| Ribavirin: An antiviral agent | Q28325218 | ||
| Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats | Q28334106 | ||
| Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats | Q28334108 | ||
| Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon | Q28344042 | ||
| 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection | Q28375545 | ||
| Mortality associated with influenza and respiratory syncytial virus in the United States | Q29615578 | ||
| RSV-induced immunopathology: dynamic interplay between the virus and host immune response | Q30309397 | ||
| Treatment of RSV pneumonia in adults--evidence of ribavirin effectiveness? | Q33689234 | ||
| Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents | Q33926422 | ||
| Respiratory syncytial virus infection in adults | Q33961877 | ||
| Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended | Q34033632 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology | Q34364942 | ||
| The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism | Q34407499 | ||
| Preventive and therapeutic strategies for respiratory syncytial virus infection | Q34476175 | ||
| Management of respiratory syncytial virus infection | Q34608152 | ||
| Respiratory syncytial virus infection: clinical features, management, and prophylaxis | Q34618126 | ||
| Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics | Q34717853 | ||
| Role of chemokines in respiratory syncytial virus disease | Q34768207 | ||
| Respiratory syncytial virus infections in children and adults | Q34826396 | ||
| Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection | Q35124942 | ||
| Antisense therapeutics: from theory to clinical practice | Q35153742 | ||
| Orally active fusion inhibitor of respiratory syncytial virus | Q35547902 | ||
| Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order | Q35613344 | ||
| Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development | Q35643045 | ||
| In search of a small-molecule inhibitor for respiratory syncytial virus | Q35917503 | ||
| Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells | Q36028877 | ||
| Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera | Q36100236 | ||
| Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. | Q36225146 | ||
| 5'-O-Monophosphoryladenylyl(2' goes to 5')adenylyl(2' goes to 5')adenosine is an antagonist of the action of 5'-O-triphosphoryladenylyl-(2' goes to 5')adenylyl(2' goes to 5')adenosine and double-stranded RNA. | Q36373135 | ||
| Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P | Q36464353 | ||
| Gene expression of nonsegmented negative strand RNA viruses | Q36915590 | ||
| Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion | Q37585515 | ||
| Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion | Q37712954 | ||
| 2'-5' Oligoadenylate synthetase plays a critical role in interferon-gamma inhibition of respiratory syncytial virus infection of human epithelial cells | Q38289747 | ||
| Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides | Q38348862 | ||
| RSV entry inhibitors block F-protein mediated fusion with model membranes | Q39405860 | ||
| RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein | Q39416825 | ||
| Biochemistry and clinical applications of ribavirin | Q39460438 | ||
| Evaluation of the QuickLab RSV test, a new rapid lateral-flow immunoassay for detection of respiratory syncytial virus antigen | Q39484692 | ||
| Ribavirin: a clinical overview | Q39505179 | ||
| Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats | Q39652266 | ||
| Ribavirin causes error catastrophe during Hantaan virus replication. | Q39698441 | ||
| Respiratory syncytial virus infections in infants: Quantitation and duration of shedding | Q39996906 | ||
| Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin | Q40550868 | ||
| Respiratory syncytial virus infections in previously healthy working adults | Q40597674 | ||
| Prospects for a respiratory syncytial virus vaccine | Q40625380 | ||
| The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. | Q40643235 | ||
| Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense | Q40746893 | ||
| VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent | Q40814769 | ||
| Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection | Q40829910 | ||
| Respiratory syncytial virus (RSV) disease and prospects for its control | Q40836386 | ||
| Recruiting the 2-5A system for antisense therapeutics | Q41522925 | ||
| Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats | Q41644488 | ||
| Interactions between RSV infection, asthma, and atopy: unraveling the complexities | Q42795514 | ||
| The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen | Q43545743 | ||
| The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus | Q43591295 | ||
| Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). | Q43724047 | ||
| Pharmacokinetics of a benzodithiin (RD3-0028) following aerosol treatment in rat. | Q43872054 | ||
| Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration | Q44443130 | ||
| Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus | Q44668921 | ||
| Systemic corticosteroids in infant bronchiolitis: A meta-analysis | Q45041128 | ||
| Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases | Q45657243 | ||
| Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults | Q45721944 | ||
| Respiratory syncytial virus infections--an underdiagnosed entity? | Q45730895 | ||
| Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine | Q45734744 | ||
| Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study | Q45734830 | ||
| Ribavirin in ventilated respiratory syncytial virus bronchiolitis. A randomized, placebo-controlled trial | Q45747450 | ||
| Mouse model of respiratory syncytial virus infection to evaluate antiviral activity in vivo | Q45748055 | ||
| Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden | Q45752482 | ||
| Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein | Q45752849 | ||
| Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice | Q45832607 | ||
| Synthesis of azole nucleoside 5'-monophosphate mimics (P1Ms) and their inhibitory properties of IMP dehydrogenases | Q46660162 | ||
| Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens | Q47978757 | ||
| Background of the antisense oligonucleotide approach to chemotherapy | Q48829741 | ||
| Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity. | Q50584066 | ||
| Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. | Q51666343 | ||
| Blockage of NF-kappa B signaling by selective ablation of an mRNA target by 2-5A antisense chimeras | Q58666576 | ||
| DNA antisense therapy for asthma in an animal model | Q59060753 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 207-220 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Antisense approaches for inhibiting respiratory syncytial virus | |
| P478 | volume | 5 |
| Q90668023 | Development and verification of real-time PCR assay for identification of viral agents causing acute respiratory infections in human beings |
| Q36174346 | Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics |
| Q45400554 | Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme DZ1133 in mice |
| Q33776507 | Pharmacologic advances in the treatment and prevention of respiratory syncytial virus |
| Q37333053 | RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy |
Search more.